Purchase Order 75N91021P00827
Award Date
9/20/21
Potential Completion Date
10/20/21
Potential Value
$238K
Federal Agency
National Cancer Institute
Awardee
Illumina, Inc.
Ultimate Awardee
Not listed
NAICS Category
334516 - Analytical Laboratory Instrument Manufacturing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services, National Institutes of Health, National Cancer Institute awarded a firm-fixed-price purchase order to Illumina, Inc., a for-profit manufacturer of sequencing and genomic analysis instruments and reagents, to provide an Illumina NextSeq 2000 genetic analysis sequencer. The sequencer will be used to acquire whole genome, whole exome, and whole transcriptome data to support the National Cancer Institute's efforts to develop novel cancer...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute (NCI) awarded a firm fixed-price purchase order to Illumina, Inc., a for-profit manufacturer of genomics sequencing systems and reagents, for the procurement of an Illumina NextSeq 550 sequencing system. The $266,475 award was made on May 24, 2019 with an August 22, 2019 completion date. This purchase will complement the NCI's existing Illumina NextSeq 500 and MiSeq instruments used by...
This is a firm fixed price delivery order awarded by the National Cancer Institute, a component of the National Institutes of Health (NIH), to Illumina, Inc. for $35,017.88. The award does not have a set-aside designation. Illumina is a manufacturer and provider of genetic sequencing and analysis instruments and reagents. Under this order, Illumina is providing various NextSeq, NovaSeq, MiSeq, and iSeq sequencing systems, reagents, and related products and services to support genomic...
This is a $202,000.00 firm fixed price purchase order awarded by the National Cancer Institute (NCI), a civilian agency within the National Institutes of Health (NIH), to Illumina, Inc. for the provision of an Illumina NextSeq 500 sequencing system. The contract has no set-aside designation. Through past contract awards, Illumina has provided a range of genomic sequencing instruments, reagents, and support services to various federal agencies including the NIH, Centers for Disease Control and...
The National Cancer Institute, a component of the National Institutes of Health within the Department of Health and Human Services, awarded a $395,850 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The contract calls for Illumina to provide two Illumina NextSeq2000 Next Generation Benchtop High-Throughput Sequencing Instruments or equivalent equipment to support genomic research at NCI facilities. The solicitation sought quotes for the sequencing instruments to...
This is a $28,749.60 firm-fixed-price delivery order contract awarded by the National Cancer Institute (NCI) to Illumina, Inc., a manufacturer of sequencing and array-based genomic analysis solutions. The contract is for the provision of laboratory equipment and supplies, with no set-aside designation. Through this award, Illumina will provide the NCI with a range of its NextSeq, NovaSeq, MiSeq, and iSeq sequencing systems, as well as accompanying reagents, consumables, sample prep kits,...
This is a $263,862.50 firm fixed price purchase order awarded by the National Cancer Institute (NCI), a civilian agency under the National Institutes of Health (NIH), to Illumina, Inc. The contract is for the procurement of laboratory equipment and supplies, specifically various Illumina sequencing systems, reagents, and consumables to support the NCI Surgery Branch's genetic sequencing needs. The award does not have a set-aside designation. Illumina has previously received other prime federal...
Illumina, Inc. has been awarded a $124,564.88 firm fixed price delivery order by the Department of Health and Human Services' National Institutes of Health National Cancer Institute for reagents and consumables. As the sole manufacturer of the sequencing instruments utilized by the agency, Illumina will provide proprietary supplies to support genomic sequencing and analysis at the agency's San Diego, California facility. No set-aside designation was applied to this order issued under an existing...
This firm fixed price delivery order was awarded by the National Cancer Institute, a civilian agency within the National Institutes of Health, to Illumina, Inc., a for-profit manufacturer of genetic sequencing instruments and reagents. The $3,846.34 award is for the provision of Illumina's NextSeq, NovaSeq, MiSeq, and iSeq sequencing systems, along with accompanying reagents, consumables, sample prep kits, sequencing chips, support plans, maintenance services, and bioinformatics products....
This is a firm fixed price delivery order contract awarded by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to Illumina, Inc., a for-profit manufacturer of genetic analysis instruments and reagents. The contract, valued at $81,640.80, is for the provision of NEXTSEQ 500/500 sequencing systems and related catalog items. The award has no set-aside designation. Illumina has previously provided sequencing systems and services to support...